Phosphorylation of mutant huntingtin at serine 116 modulates neuronal toxicity

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Watkin, Erin E ^a   Arbez, Nicolas ^a   Waldron Roby, Elaine ^a   O'Meally, Robert ^a   Ratovitski, Tamara ^a   Cole, Robert N ^a   Ross, Christopher A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; HUNTINGTIN; MUTANT PROTEIN; POLYGLUTAMINE; SERINE;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CELL STRAIN HEK293; CYTOTOXICITY TEST; EMBRYO; ENZYME MODIFICATION; HUMAN; HUMAN CELL; MASS SPECTROMETRY; MOUSE; NERVE CELL NECROSIS; NEUROTOXICITY; NONHUMAN; PRIMARY CELL CULTURE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SITE DIRECTED MUTAGENESIS; TIME LAPSE IMAGING;

AMINO ACID SEQUENCE; ANIMALS; CELL DEATH; CELLS, CULTURED; HEK293 CELLS; HUMANS; HUNTINGTON DISEASE; MICE; MOLECULAR SEQUENCE DATA; NERVE TISSUE PROTEINS; NEURONS; PEPTIDES; PHOSPHORYLATION; POINT MUTATION; SERINE;

EID: 84895546954     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088284     Document Type: Article

References (73)

1. Ross CA, Tabrizi SJ (2011) Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 10: 83-98.
2. Gusella JF, MacDonald ME (2006) Huntington's disease: seeing the pathogenic process through a genetic lens. Trends Biochem Sci 31: 533-540. (Pubitemid 44279978)
3. MacDonald ME (2003) Huntingtin: alive and well and working in middle management. Sci STKE 2003: pe48.
4. Walker FO (2007) Huntington's Disease. Semin Neurol 27: 143-150.
5. Imarisio S, Carmichael J, Korolchuk V, Chen CW, Saiki S, et al. (2008) Huntington's disease: from pathology and genetics to potential therapies. Biochem J 412: 191-209. (Pubitemid 351758226)
6. Krobitsch S, Kazantsev AG (2011) Huntington's disease: From molecular basis to therapeutic advances. Int J Biochem Cell Biol 43: 20-24.
7. Shang H, Danek A, Landwehrmeyer B, Burgunder JM (2012) Huntington's disease: new aspects on phenotype and genotype. Parkinsonism Relat Disord 18 Suppl 1: S107-109.
8. Finkbeiner S (2011) Huntington's Disease. Cold Spring Harb Perspect Biol 3.
9. Zuccato C, Valenza M, Cattaneo E (2005) Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev 90: 905-981.
10. Ross CA, Shoulson I (2009) Huntington disease: pathogenesis, biomarkers, and approaches to experimental therapeutics. Parkinsonism Relat Disord 15 Suppl 3: S135-138.
11. Cowan CM, Raymond LA (2006) Selective neuronal degeneration in Huntington's disease. Curr Top Dev Biol 75: 25-71. (Pubitemid 44375081)
12. Reiner A, Dragatsis I, Dietrich P (2011) Genetics and neuropathology of Huntington's disease. Int Rev Neurobiol 98: 325-372.
13. Vonsattel JP, Keller C, Cortes Ramirez EP (2011) Huntington's disease - neuropathology. Handb Clin Neurol 100: 83-100.
14. Ehrlich ME (2012) Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease. Neurotherapeutics 9: 270-284.
15. The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 72: 971-983.
16. Borrell-Pages M, Zala D, Humbert S, Saudou F (2006) Huntington's disease: from huntingtin function and dysfunction to therapeutic strategies. Cell Mol Life Sci 63: 2642-2660. (Pubitemid 44800717)
17. Zheng L, Diamond JM, Denton DL (2013) Evaluation of whole effluent toxicity data characteristics and use of Welch's T-test in the test of significant toxicity analysis. Environ Toxicol Chem 32: 468-474.
18. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, et al. (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277: 1990-1993. (Pubitemid 27449140)
19. Qin ZH, Gu ZL (2004) Huntingtin processing in pathogenesis of Huntington disease. Acta Pharmacol Sin 25: 1243-1249. (Pubitemid 39361794)
20. Waldron-Roby E, Ratovitski T, Wang X, Jiang M, Watkin E, et al. (2012) Transgenic mouse model expressing the caspase 6 fragment of mutant huntingtin. J Neurosci 32: 183-193.
21. Ratovitski T, Nakamura M, D'Ambola J, Chighladze E, Liang Y, et al. (2007) N-terminal proteolysis of full-length mutant huntingtin in an inducible PC12 cell model of Huntington's disease. Cell Cycle 6: 2970-2981.
22. Ratovitski T, Gucek M, Jiang H, Chighladze E, Waldron E, et al. (2009) Mutant huntingtin N-terminal fragments of specific size mediate aggregation and toxicity in neuronal cells. J Biol Chem 284: 10855-10867.
23. Graham RK, Deng Y, Slow EJ, Haigh B, Bissada N, et al. (2006) Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 125: 1179-1191. (Pubitemid 43866195)
24. Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, et al. (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90: 537-548. (Pubitemid 27347243)
25. Schilling G, Becher MW, Sharp AH, Jinnah HA, Duan K, et al. (1999) Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet 8: 397-407. (Pubitemid 29097327)
26. Crook ZR, Housman D (2011) Huntington's disease: can mice lead the way to treatment? Neuron 69: 423-435.
27. Heng MY, Detloff PJ, Albin RL (2008) Rodent genetic models of Huntington disease. Neurobiol Dis 32: 1-9.
28. Arrasate M, Finkbeiner S (2012) Protein aggregates in Huntington's disease. Exp Neurol 238: 1-11.
29. Ross CA, Poirier MA (2004) Protein aggregation and neurodegenerative disease. Nature Med 10: S10-S17. (Pubitemid 38901862)
30. Poirier MA, Jiang H, Ross CA (2005) A structure-based analysis of huntingtin mutant polyglutamine aggregation and toxicity: evidence for a compact beta-sheet structure. Hum Mol Genet 14: 765-774. (Pubitemid 40403273)
31. Bossy-Wetzel E, Petrilli A, Knott AB (2008) Mutant huntingtin and mitochondrial dysfunction. Trends Neurosci 31: 609-616.
32. Nucifora LG, Burke KA, Feng X, Arbez N, Zhu S, et al. (2012) Identification of novel potentially toxic oligomers formed in vitro from mammalian-derived expanded huntingtin exon-1 protein. J Biol Chem 287: 16017-16028.
33. The HD iPsc Consortium (2012) Induced Pluripotent Stem Cells from Patients with Huntington's Disease Show CAG-Repeat-Expansion-Associated Phenotypes. Cell Stem Cell 11: 264-278.
34. Cattaneo E, Zuccato C, Tartari M (2005) Normal huntingtin function: an alternative approach to Huntington's disease. Nat Rev Neurosci 6: 919-930. (Pubitemid 41753086)
35. Caviston JP, Holzbaur EL (2009) Huntingtin as an essential integrator of intracellular vesicular trafficking. Trends Cell Biol 19: 147-155.
36. Shirasaki DI, Greiner ER, Al-Ramahi I, Gray M, Boontheung P, et al. (2012) Network organization of the huntingtin proteomic interactome in mammalian brain. Neuron 75: 41-57.
37. Culver BP, Savas JN, Park SK, Choi JH, Zheng S, et al. (2012) Proteomic analysis of wild-type and mutant huntingtin-associated proteins in mouse brains identifies unique interactions and involvement in protein synthesis. J Biol Chem 287: 21599-21614.
38. Ratovitski T, Chighladze E, Arbez N, Boronina T, Herbrich S, et al. (2012) Huntingtin protein interactions altered by polyglutamine expansion as determined by quantitative proteomic analysis. Cell Cycle 11: 2006-2021.
39. Ehrnhoefer DE, Skotte NH, Savill J, Nguyen YT, Ladha S, et al. (2011) A quantitative method for the specific assessment of caspase-6 activity in cell culture. PLoS One 6: e27680.
40. Schilling B, Gafni J, Torcassi C, Cong X, Row RH, et al. (2006) Huntingtin phosphorylation sites mapped by mass spectrometry. Modulation of cleavage and toxicity. J Biol Chem 281: 23686-23697. (Pubitemid 44274144)
41. Mitsui K, Doi H, Nukina N (2006) Proteomics of polyglutamine aggregates. Methods Enzymol 412: 63-76. (Pubitemid 44548574)
42. Wang Y, Lin F, Qin ZH (2010) The role of post-translational modifications of huntingtin in the pathogenesis of Huntington's disease. Neurosci Bull 26: 153-162.
43. Young FB, Franciosi S, Spreeuw A, Deng Y, Sanders S, et al. (2012) Low levels of human HIP14 are sufficient to rescue neuropathological, behavioural, and enzymatic defects due to loss of murine HIP14 in Hip14-/- mice. PLoS One 7: e36315.
44. Dong G, Callegari E, Gloeckner CJ, Ueffing M, Wang H (2012) Mass spectrometric identification of novel posttranslational modification sites in Huntingtin. Proteomics 12: 2060-2064.
45. Cong X, Held JM, DeGiacomo F, Bonner A, Chen JM, et al. (2011) Mass spectrometric identification of novel lysine acetylation sites in huntingtin. Mol Cell Proteomics 10: M111 009829.
46. Rangone H, Poizat G, Troncoso J, Ross CA, MacDonald ME, et al. (2004) The serum- and glucocorticoid-induced kinase SGK inhibits mutant huntingtin-induced toxicity by phosphorylating serine 421 of huntingtin. Eur J Neurosci 19: 273-279. (Pubitemid 38177866)
47. Colin E, Zala D, Liot G, Rangone H, Borrell-Pages M, et al. (2008) Huntingtin phosphorylation acts as a molecular switch for anterograde/retrograde transport in neurons. EMBO J 27: 2124-2134.
48. Zala D, Colin E, Rangone H, Liot G, Humbert S, et al. (2008) Phosphorylation of mutant huntingtin at S421 restores anterograde and retrograde transport in neurons. Hum Mol Genet 17: 3837-3846. (Pubitemid 352762847)
49. Warby SC, Doty CN, Graham RK, Shively J, Singaraja RR, et al. (2009) Phosphorylation of huntingtin reduces the accumulation of its nuclear fragments. Mol Cell Neurosci 40: 121-127.
50. Humbert S, Bryson EA, Cordelieres FP, Connors NC, Datta SR, et al. (2002) The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev Cell 2: 831-837. (Pubitemid 34650078)
51. Pardo R, Colin E, Regulier E, Aebischer P, Deglon N, et al. (2006) Inhibition of calcineurin by FK506 protects against polyglutamine-huntingtin toxicity through an increase of huntingtin phosphorylation at S421. J Neurosci 26: 1635-1645. (Pubitemid 43237034)
52. Metzler M, Gan L, Mazarei G, Graham RK, Liu L, et al. (2010) Phosphorylation of huntingtin at Ser421 in YAC128 neurons is associated with protection of YAC128 neurons from NMDA-mediated excitotoxicity and is modulated by PP1 and PP2A. J Neurosci 30: 14318-14329.
53. Jablonski MR, Cooper L, Jacob DA (2011) NMDA receptor excitotoxicity: impact on phosphatase activity and phosphorylation of huntingtin. J Neurosci 31: 4357-4359.
54. Luo S, Vacher C, Davies JE, Rubinsztein DC (2005) Cdk5 phosphorylation of huntingtin reduces its cleavage by caspases: implications for mutant huntingtin toxicity. J Cell Biol 169: 647-656. (Pubitemid 41002857)
55. Anne SL, Saudou F, Humbert S (2007) Phosphorylation of huntingtin by cyclin-dependent kinase 5 is induced by DNA damage and regulates wild-type and mutant huntingtin toxicity in neurons. J Neurosci 27: 7318-7328. (Pubitemid 47037570)
56. Maiuri T, Woloshansky T, Xia J, Truant R (2012) The huntingtin N17 domain is a multifunctional CRM1 and Ran-dependent nuclear and cilial export signal. Hum Mol Genet 22: 1383-1394.
57. Khoshnan A, Patterson PH (2011) The role of IkappaB kinase complex in the neurobiology of Huntington's disease. Neurobiol Dis 43: 305-311.
58. Atwal RS, Desmond CR, Caron N, Maiuri T, Xia J, et al. (2011) Kinase inhibitors modulate huntingtin cell localization and toxicity. Nat Chem Biol 7: 453-460.
59. Greiner ER, Yang XW (2011) Huntington's disease: flipping a switch on huntingtin. Nat Chem Biol 7: 412-414.
60. Havel LS, Wang CE, Wade B, Huang B, Li S, et al. (2011) Preferential accumulation of N-terminal mutant huntingtin in the nuclei of striatal neurons is regulated by phosphorylation. Hum Mol Genet 20: 1424-1437.
61. Gu X, Greiner ER, Mishra R, Kodali R, Osmand A, et al. (2009) Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice. Neuron 64: 828-840.
62. Aiken CT, Steffan JS, Guerrero CM, Khashwji H, Lukacsovich T, et al. (2009) Phosphorylation of threonine 3: implications for Huntingtin aggregation and neurotoxicity. J Biol Chem 284: 29427-29436.
63. Di Pardo A, Maglione V, Alpaugh M, Horkey M, Atwal RS, et al. (2012) Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease mice. Proc Natl Acad Sci U S A 109: 3528-3533.
64. Thompson LM, Aiken CT, Kaltenbach LS, Agrawal N, Illes K, et al. (2009) IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. J Cell Biol 187: 1083-1099.
65. Mishra R, Hoop CL, Kodali R, Sahoo B, van der Wel PC, et al. (2012) Serine phosphorylation suppresses huntingtin amyloid accumulation by altering protein aggregation properties. J Mol Biol 424: 1-14.
66. Peters MF, Ross CA (2001) Isolation of a 40-kDa Huntingtin-associated protein. J Biol Chem 276: 3188-3194.
67. Guo Z, Rudow G, Pletnikova O, Codispoti KE, Orr BA, et al. (2012) Striatal neuronal loss correlates with clinical motor impairment in Huntington's disease. Mov Disord 27: 1379-1386.
68. Miller J, Arrasate M, Shaby BA, Mitra S, Masliah E, et al. (2010) Quantitative relationships between huntingtin levels, polyglutamine length, inclusion body formation, and neuronal death provide novel insight into huntington's disease molecular pathogenesis. J Neurosci 30: 10541-10550.
69. Arrasate M, Finkbeiner S (2005) Automated microscope system for determining factors that predict neuronal fate. Proc Natl Acad Sci U S A 102: 3840-3845. (Pubitemid 40354698)
70. Emamian ES, Kaytor MD, Duvick LA, Zu T, Tousey SK, et al. (2003) Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice. Neuron 38: 375-387. (Pubitemid 36579141)
71. Martin L, Latypova X, Wilson CM, Magnaudeix A, Perrin ML, et al. (2013) Tau protein kinases: involvement in Alzheimer's disease. Ageing Res Rev 12: 289-309.
72. Chau KY, Ching HL, Schapira AH, Cooper JM (2009) Relationship between alpha synuclein phosphorylation, proteasomal inhibition and cell death: relevance to Parkinson's disease pathogenesis. J Neurochem 110: 1005-1013.
73. Fox JH, Connor T, Chopra V, Dorsey K, Kama JA, et al. (2010) The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease. Mol Neurodegener 5: 26.